News - February, 2026

Cipio Partners invests in Dawn Health to fuel the next phase of growth for AI-driven commercial and clinical companion applications

Dawn Health, a global leader in digital health, today announced a €21.5 million growth investment, following a new investment from Cipio Partners, joining the existing owner group alongside Chr. Augustinus Fabrikker (CAF), the Export and Investment Fund of Denmark (EIFO), and Trifork. The investment builds on the growth funding provided by the company’s existing owners and will support Dawn Health’s continued expansion as an AI-enabled patient companion partner for pharma across clinical, medical, and commercial activities.

Over the past years, Dawn Health has built a trusted platform and ecosystem supporting the world's leading pharma companies in driving value across use cases spanning the clinical to commercial continuum. As the platform is widely adopted by pharma as well as leading technology and AI partners, the investment will further accelerate product innovation and continued value creation for these partners.
 

Cipio Partners brings extensive experience in scaling global B2B technology companies and sees Dawn Health uniquely positioned to become a long-term category leader in regulated digital health.
 

“We are very excited to welcome Cipio Partners as an investor,” said Alexander Mandix Hansen, CEO of Dawn Health. “We see a strong alignment between Cipio’s capabilities and ambitions and the strategy of our company, as well as the vision of our existing owners.”
 

Dawn Health’s technology is already deployed across multiple therapeutic areas, supporting patients, healthcare professionals, and pharma teams with regulatory-grade digital solutions across disease management, therapy support, and clinical research.
 

“Dawn Health stands out as a company with a very strong product foundation, deep regulatory expertise, and trusted, long-standing relationships with global pharma leaders,” said Dr. Ansgar Kirchheim, Partner at Cipio Partners. “We see a clear opportunity to support Dawn Health in further scaling its SaaS offer and expanding even more into the clinical trial space, where digital and data-driven solutions are becoming increasingly critical. We are excited to partner with Dawn Health’s great team on the next phase of growth.”
 

The investment reinforces Dawn Health’s long-term strategy of building scalable, compliant digital health products that support the full pharma value chain, from clinical development to commercialisation, while continuing to improve outcomes for patients worldwide.

About Cipio Partners

Founded in 2003, Cipio Partners is a leading investment management and advisory firm for European growth capital & minority buyouts for technology companies. Cipio Partners targets European growth stage technology businesses with €10-50 million in revenue and makes initial investments ranging from €5-15 million. Cipio Partners operates from offices in Munich and Luxembourg. Further information is available at www.cipiopartners.com.

About Dawn Health

Dawn Health is a global leader in digital health, delivering digital products that support the full lifecycle of a therapy — from clinical research to market adoption and long-term disease management. Dawn Health’s solutions include Software as a Medical Device (SaMD) and other regulated digital health products designed to meet high regulatory standards while enabling scale and faster time to market. Working closely with the life sciences industry, Dawn Health builds digital health products that support people living with chronic conditions, with a strong focus on empathy, usability, and human-centric design.